Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1
US10358648B2 · kind B2 · utility
8Cited by
2References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 1, 2017 |
| Grant date | Jul 23, 2019 |
| Priority date | — |
| Expiry date | Feb 1, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/3521
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit IL4Rα, TRPA1, and/or F2RL1 expression and are therefore useful for treating atopic dermatitis or asthma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.